Last edition
News about "PCSK9 base editing therapy"
Eli Lilly and Company reports that a single dose of investigational gene-editing therapy VERVE-102 delivered sustained reductions in PCSK9 and LDL cholesterol for up to 18 months in high-risk cardiovascular patients.
PCSK9 Base Editing Therapy | 26/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members